Цитата:
Сообщение от vmark
А это Вам зачем?
|
In April 2008, Oncophage® (vitespen; formerly HSPPC-96) was approved in Russia for the treatment of kidney cancer patients at intermediate risk for disease recurrence. The company expects to launch Oncophage in Russia in the second half of 2008. Oncophage is approved only in Russia and Antigenics expects to submit to the European Regulatory Agency before the end of 2008.